You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 14, 2025

Karyopharm Theraps Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Karyopharm Theraps
International Patents:125
US Patents:10
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Karyopharm Theraps

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-002 Apr 15, 2021 RX Yes No 10,519,139 ⤷  Try for Free Y Y ⤷  Try for Free
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-002 Apr 15, 2021 RX Yes No 11,746,102 ⤷  Try for Free ⤷  Try for Free
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-003 Apr 15, 2021 RX Yes No 11,753,401 ⤷  Try for Free Y ⤷  Try for Free
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-001 Jul 3, 2019 RX Yes No 11,034,660 ⤷  Try for Free ⤷  Try for Free
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-001 Jul 3, 2019 RX Yes No 11,753,401 ⤷  Try for Free Y ⤷  Try for Free
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-001 Jul 3, 2019 RX Yes No 11,787,771 ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Karyopharm Theraps Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2736887 21C1042 France ⤷  Try for Free PRODUCT NAME: SELINEXOR OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/21/1537 20210329; FIRST REGISTRATION: FR - EU/1/21/1537 20210329
2736887 CA 2021 00031 Denmark ⤷  Try for Free PRODUCT NAME: SELINEXOR ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1537 20210329
2736887 2021C/532 Belgium ⤷  Try for Free DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME
2736887 CR 2021 00031 Denmark ⤷  Try for Free PRODUCT NAME: SELINEXOR ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1537 20210329
2736887 301119 Netherlands ⤷  Try for Free DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME
2736887 PA2021007,C2736887 Lithuania ⤷  Try for Free PRODUCT NAME: SELINEKSORAS; REGISTRATION NO/DATE: EU/1/21/1537 20210326
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Karyopharm Therapeutics – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, Karyopharm Therapeutics has emerged as a notable player, carving out a unique niche with its innovative approach to cancer treatment. This comprehensive analysis delves into Karyopharm's market position, strengths, and strategic insights, offering a detailed look at how this biopharmaceutical company is navigating the competitive landscape.

Karyopharm Therapeutics: A Brief Overview

Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Founded with a focus on developing innovative treatments, the company has made significant strides in the oncology field, particularly in hematologic malignancies and solid tumors.

Core Technology: SINE Platform

At the heart of Karyopharm's innovation is its proprietary Selective Inhibitor of Nuclear Export (SINE) technology. This groundbreaking platform targets nuclear transport mechanisms, offering a unique approach to drug development that sets Karyopharm apart from its competitors[2].

"Karyopharm Therapeutics concentrates on developing innovative therapies targeting nuclear transport mechanisms. As of 2024, the company has 3 clinical-stage drug candidates in oncology pipeline, 2 FDA-approved medications, and research programs targeting rare diseases and cancer." - Source: DCF Modeling[2]

Market Position and Financial Performance

Revenue Growth and Market Capitalization

Karyopharm has shown promising financial performance, with preliminary unaudited full-year 2024 total revenue expected to be approximately $145 million[3]. This figure includes U.S. XPOVIO® (selinexor) net product revenue of approximately $113 million, demonstrating the company's growing commercial success.

As of February 7, 2025, Karyopharm's market capitalization stood at $79.07 million[1]. While this places the company in the small-cap category, it's important to note the potential for growth given the company's strategic initiatives and pipeline developments.

Comparative Market Position

When compared to industry peers, Karyopharm's market capitalization is significantly smaller than companies like Bruker Corp ($8.699B) and Ionis Pharmaceuticals Inc ($5.699B)[1]. However, this also suggests substantial room for growth as the company continues to advance its pipeline and expand its commercial presence.

Strengths and Competitive Advantages

Innovative Drug Discovery Platform

Karyopharm's SINE technology provides a unique approach to drug development, setting the company apart in a crowded field. This innovative platform has led to the development of multiple clinical-stage drug candidates and FDA-approved medications[2].

Strong Intellectual Property Portfolio

The company boasts a robust intellectual property portfolio, which is crucial in the pharmaceutical industry. As of 2024, Karyopharm held:

  • 42 granted patents worldwide
  • Patent expiration ranges from 2030 to 2041
  • Geographic coverage including the United States, Europe, and Japan[2]

This extensive patent protection provides Karyopharm with a significant competitive advantage, allowing for long-term market exclusivity for its innovative therapies.

FDA-Approved Product: Xpovio (Selinexor)

Xpovio, Karyopharm's flagship product, has demonstrated significant clinical effectiveness:

  • FDA approval for multiple myeloma in 2019
  • Expanded indications for relapsed/refractory patients
  • Estimated annual revenue of $78.5 million in 2023[2]

The success of Xpovio not only provides a steady revenue stream but also validates Karyopharm's drug development approach, potentially paving the way for future approvals.

Experienced Management Team

Karyopharm's leadership team brings a wealth of experience to the table:

  • Average industry experience of 22 years
  • 4 members with prior leadership roles in major pharmaceutical companies
  • Collective publication record of 87 peer-reviewed scientific publications[2]

This depth of experience and industry knowledge positions Karyopharm well for navigating the complex pharmaceutical landscape and driving future growth.

Strategic Initiatives and Future Outlook

Focus on Combination Therapies

Karyopharm is strategically positioning itself in the combination therapy space, particularly in myelofibrosis. The company is on track to complete enrollment in the first half of 2025 for its Phase 3 SENTRY trial, which evaluates selinexor in combination with ruxolitinib in patients with JAKi-Naïve Myelofibrosis[3].

Expanding Indications: Endometrial Cancer

The company is also making strides in the endometrial cancer space. Karyopharm remains engaged with the FDA regarding the evolving treatment landscape in endometrial cancer, with plans to provide an update on its program in the first quarter of 2025[3].

Pipeline Diversification

Beyond its core oncology focus, Karyopharm is exploring opportunities in rare diseases:

  • KPT-9274 (padnarsertib) granted Rare Pediatric Disease Designations for Rhabdomyosarcoma and Ewing sarcoma
  • Orphan Drug Designations for soft tissue sarcoma and Ewing sarcoma[3]

This diversification strategy could open up new market opportunities and revenue streams for the company.

Challenges and Market Dynamics

Competitive Landscape

The oncology market is highly competitive, with numerous large pharmaceutical companies and biotechs vying for market share. Karyopharm faces competition from established players like Amgen, Bristol Myers Squibb, Roche, Gilead Sciences, and Novartis[7].

Financial Constraints

As a smaller player in the industry, Karyopharm faces financial constraints that could impact its ability to fund extensive R&D and marketing efforts. The company's reliance on external funding to support its R&D efforts could pose challenges in advancing its pipeline[7].

Clinical and Regulatory Risks

Like all pharmaceutical companies, Karyopharm faces inherent risks associated with drug development, including the possibility of trial failures and regulatory setbacks[7]. The success of ongoing clinical trials, particularly in myelofibrosis and endometrial cancer, will be crucial for the company's future growth.

Market Opportunities and Growth Potential

Expanding Cancer Market

The increasing prevalence of cancer presents a significant market opportunity for Karyopharm. The demand for innovative therapies continues to rise, providing a favorable environment for the company's products[7].

Potential in Emerging Markets

Expanding into emerging markets where access to innovative treatments is limited could provide significant growth opportunities for Karyopharm[7]. This strategy could help the company increase its global footprint and diversify its revenue streams.

Exploration of New Indications

Karyopharm's SINE technology platform has potential applications beyond oncology. The company could explore opportunities in neurodegenerative diseases and viral infections, further expanding its market reach[7].

Strategic Partnerships and Collaborations

Karyopharm has demonstrated a commitment to strategic partnerships, which can enhance its R&D capabilities and provide financial support[7]. These collaborations with leading pharmaceutical companies and research institutions could be key to the company's future success.

Investor Sentiment and Analyst Perspectives

Price Targets and Analyst Ratings

As of December 23, 2024, the average one-year price target for Karyopharm Therapeutics was $4.59, with forecasts ranging from a low of $2.02 to a high of $7.35[6]. This suggests potential upside from the current share price, although it's important to note the inherent volatility in biotech stocks.

Institutional Ownership

Karyopharm has attracted significant institutional interest, with 165 institutional owners and shareholders holding a total of 67,210,890 shares. Major shareholders include Vanguard Group Inc, Eversept Partners, LP, and Palo Alto Investors LP[6].

Future Outlook and Strategic Priorities

Redefining the Standard of Care in Myelofibrosis

Karyopharm's top strategic objective for 2025 is to deliver on the transformative opportunity to redefine the standard of care in myelofibrosis. The company is focused on high-quality clinical trial execution and engaging with investigators to complete enrollment in its Phase 3 SENTRY trial[3].

Commercialization Capabilities

Karyopharm is leveraging its demonstrated commercialization capabilities to prepare for potential rapid launches of new indications. This includes building on its multiple myeloma foundation to expand into new therapeutic areas[3].

Cost Optimization and Financial Management

The company expects to deliver meaningful reductions in selling, general, and administrative expenses in 2024 as it focuses its resources on research and development initiatives and overall cost optimization opportunities[3].

Key Takeaways

  1. Karyopharm Therapeutics has established a unique position in the pharmaceutical industry with its innovative SINE technology platform.

  2. The company's FDA-approved product, Xpovio, has demonstrated clinical effectiveness and provides a steady revenue stream.

  3. Karyopharm's strong intellectual property portfolio and experienced management team provide significant competitive advantages.

  4. The company is strategically focusing on combination therapies and expanding indications, particularly in myelofibrosis and endometrial cancer.

  5. While facing challenges such as intense competition and financial constraints, Karyopharm has significant growth potential in the expanding cancer market and potential new indications.

  6. Strategic partnerships and a focus on cost optimization are key elements of Karyopharm's future strategy.

  7. The success of ongoing clinical trials and regulatory approvals will be crucial for the company's future growth and market position.

FAQs

  1. Q: What is Karyopharm Therapeutics' main technology platform? A: Karyopharm's main technology platform is the Selective Inhibitor of Nuclear Export (SINE) technology, which targets nuclear transport mechanisms for drug development.

  2. Q: How many FDA-approved medications does Karyopharm currently have? A: As of 2024, Karyopharm has 2 FDA-approved medications.

  3. Q: What is Karyopharm's market capitalization as of February 2025? A: Karyopharm's market capitalization was $79.07 million as of February 7, 2025.

  4. Q: What is Karyopharm's primary focus for 2025? A: Karyopharm's top strategic objective for 2025 is to deliver on the transformative opportunity to redefine the standard of care in myelofibrosis.

  5. Q: How many institutional owners does Karyopharm have? A: Karyopharm has 165 institutional owners and shareholders that have filed 13D/G or 13F forms with the SEC.

Sources cited: [1] https://ycharts.com/companies/KPTI/market_cap [2] https://dcfmodeling.com/products/kpti-swot-analysis [3] https://www.prnewswire.com/news-releases/karyopharm-announces-preliminary-unaudited-2024-revenue-and-2025-objectives-302348582.html [6] https://fintel.io/s/us/kpti [7] https://pitchgrade.com/companies/karyopharm-therapeutics-inc

Last updated: 2025-02-12

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.